Antibodies can cause damage to the kidneys in several glomerular diseases. Researchers are working to see if a new medicine that changes the way B cells make antibodies can decrease the damage to the kidneys.
The PIONEER study is a clinical trial for people living with one of the following glomerular diseases causing damage to the kidneys:
This study tests an investigational medication, atacicept, for the treatment of multiple types of glomerular (kidney) disease and will enroll up to 250 eligible participants.
The investigational drug works by targeting the immune cells that make antibodies, called B cells. By inhibiting these cells, it may help treat kidney diseases caused by antibodies.
NOTE: All participants will receive active medication (i.e. no placebo is given).
Glomeruli are the tiny filters in the kidney that clean the blood. Glomerular disease is an umbrella term that includes many conditions that damage the glomeruli. When glomeruli are damaged protein leaks into the urine. Over time, the damage can lead to kidney failure.
Abnormal antibodies are the source of damage for several glomerular diseases.
The PIONEER study is enrolling participants with the following glomerular diseases:
IgA nephropathy (IgAN)
IgAN with vasculitis (IgAVN)
Glomeruli are the tiny filters in the kidney that clean the blood. Glomerular disease is an umbrella term that includes many conditions that damage the glomeruli. When glomeruli are damaged protein leaks into the urine. Over time, the damage can lead to kidney failure.
Abnormal antibodies are the source of damage for several glomerular diseases.
The PIONEER study is enrolling participants with the following glomerular diseases:
IgA nephropathy (IgAN)
IgAN with vasculitis (IgAVN)
Other eligibility criteria apply.
Other eligibility criteria apply.
© 2026 All rights reserved
About Us
HealthUnlocked helps millions connect, learn, and access clinical trial opportunities while building a stronger future for patient care.
Cookie Preferences
Terms & Policies
Terms and Conditions Privacy Policy